H3K27me3与EZH2免疫组化染色在IDH突变型星形细胞瘤中的预后价值
本研究纳入33例在本院接受治疗的IDH突变型星形细胞瘤患者,采用免疫组化检测H3K27me3、EZH2等标志物,结合Kaplan-Meier与Cox回归分析生存相关性。结果显示H3K27me3阳性组WHO分级与Ki-67指数更高,总生存期与无进展生存期更短;H3K27me3与EZH2双阳性与更差预后相关。
要点
- H3K27me3阳性组WHO分级与Ki-67指数显著高于阴性组(p=0.004与p=0.024)。
- H3K27me3阳性组总生存期与无进展生存期显著短于阴性组(p=0.002与p=0.026)。
- WHO 2/3级患者中H3K27me3与EZH2双阳性与更短总生存期和无进展生存期相关(p=0.0053与p=0.0048)。
核心结论
- H3K27me3阳性,尤其是H3K27me3与EZH2双阳性,可能是IDH突变型星形细胞瘤的不良预后因素。
- 作者认为H3K27me3与EZH2可作为评估IDH突变型星形细胞瘤恶性程度的候选标志物。
研究设计与样本
- 本研究纳入33例在本院接受治疗的IDH突变型星形细胞瘤患者。
- 采用免疫组化检测H3K27me3、H3K27M、EZH2、EZH抑制蛋白、IDH1-R132H、p53、ATRX、Ki-67与MTAP。
- 采用Kaplan-Meier分析与Cox回归分析评估总生存期和无进展生存期与年龄、WHO分级、切除范围及免疫组化结果的相关性。
主要发现
- 患者平均年龄为40.6±11.0岁。
- H3K27me3免疫组化阳性19例、阴性14例。
- H3K27me3阳性组WHO分级与Ki-67指数显著高于阴性组(p=0.004与p=0.024)。
- H3K27me3阳性组总生存期与无进展生存期显著短于阴性组(p=0.002与p=0.026)。
- H3K27me3与EZH2双阳性组WHO分级与Ki-67指数更高(p=0.001与p=0.024);WHO 2/3级患者中双阳性与更短总生存期和无进展生存期相关(p=0.0053与p=0.0048)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: H3 histone 27 lysine (H3K27) trimethylation (H3K27me3), which is catalyzed by enhancer of zeste homolog 2 (EZH2), regulates gene expression through epigenetic mechanisms. H3K27me3 is used as a diagnostic marker for diffuse midline glioma and as a surrogate marker to distinguish posterior fossa ependymoma A and B. However, the clinical significance of the EZH2-H3K27me3 axis in astrocytoma, IDH-mutant has not been reported, prompting this investigation. METHODS: Thirty-three patients with astrocytoma, IDH-mutant treated at our institute were included in this study. Immunohistochemistry (IHC) targeting H3K27me3, H3K27M, EZH2, EZH inhibitory protein, IDH1-R132H, p53, ATRX, Ki-67, and MTAP was performed. Kaplan-Meier analysis and Cox regression analysis were performed to analyze the correlations of overall survival (OS) and progression-free survival (PFS) with various factors, including age, World Health Organization (WHO) grade, the extent of resection, and immunohistochemical results. RESULTS: The mean patient age was 40.6 ± 11.0 years. IHC for H3K27me3 was positive in 19 patients and negative in 14 patients. The WHO grade and Ki-67 index were significantly higher in the H3K27me3-positive group (p = 0.004 and p = 0.024, respectively). OS and PFS were significantly shorter in the H3K27me3-positive group (p = 0.002 and p = 0.026, respectively). Furthermore, the H3K27me3 and EZH2 double-positive group was associated with a higher WHO grade and higher Ki-67 index (p = 0.001 and p = 0.024, respectively). In the analysis of patients with WHO grade 2/3, double positivity for H3K27me3 and EZH2 was linked to significantly shorter OS and PFS (p = 0.0053 and p = 0.0048, respectively). CONCLUSION: Positivity for H3K27me3, especially double positivity for H3K27me3 and EZH2, could be a poor prognostic factor for astrocytoma, IDH-mutant. These results suggest the utility of H3K27me3 and EZH2 as candidate markers for estimating the malignancy of astrocytoma, IDH-mutant.
引用
- Onishi S, Yamasaki F, Amatya VJ, et al. Prognostic value of immunohistochemical staining for H3K27me3 and EZH2 in astrocytoma, IDH-mutant. J Neurooncol. 2024. PMID: 39636550. doi:10.1007/s11060-024-04897-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。